When will the BETADERM patents expire, and when will generic BETADERM be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roaco	BETADERM	betamethasone valerate	CREAM;TOPICAL	018839-001	Jun 30, 1983		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Betaderm, a topical corticosteroid medication indicated for the treatment of inflammatory dermatological conditions, has established a stable market position. Its commercial performance is primarily driven by established prescribing patterns and its inclusion in formularies across major healthcare systems. Competition remains a significant factor, with numerous generic alternatives and other topical corticosteroids available, influencing pricing and market share.

What is Betaderm's Primary Indication and Mechanism of Action?

Betaderm's primary indication is the relief of inflammatory manifestations of corticosteroid-responsive dermatoses. These conditions include psoriasis, eczema, dermatitis, and seborrheic dermatitis. The active pharmaceutical ingredient, betamethasone valerate, is a potent synthetic corticosteroid that exerts its therapeutic effects through anti-inflammatory, antipruritic, and vasoconstrictive actions. Betamethasone valerate is a Group II corticosteroid, indicating high potency, which facilitates rapid and effective reduction of inflammatory skin symptoms [1]. The mechanism involves the binding of the corticosteroid to intracellular glucocorticoid receptors, which then translocate to the nucleus. This interaction modulates gene expression, leading to the inhibition of pro-inflammatory mediators such as cytokines, chemokines, and prostaglandins, while simultaneously promoting the synthesis of anti-inflammatory proteins [2].

What is the Global Market Size and Growth Projection for Betaderm?

The global market for topical corticosteroids, including Betaderm, is substantial and projected for steady growth. While specific revenue figures for Betaderm as a standalone product are not publicly disclosed by its manufacturers, the broader topical corticosteroids market was valued at approximately USD 5.2 billion in 2022 and is anticipated to reach USD 7.3 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.3% during the forecast period [3]. This growth is influenced by the increasing prevalence of skin disorders globally and greater awareness of dermatological treatments. Betaderm benefits from this overall market trend.

Key Market Drivers:

Rising Incidence of Dermatological Conditions: An increasing global population and higher rates of diagnosis for conditions like eczema and psoriasis directly correlate with demand for effective topical treatments.
Aging Population: The aging demographic is often associated with a higher incidence of various inflammatory skin conditions, contributing to sustained demand for topical corticosteroids.
Increased Healthcare Expenditure: Growing healthcare spending in both developed and developing economies expands access to prescription medications like Betaderm.
Availability of Generic Versions: While competition, the presence of generic Betaderm also expands its accessibility and user base, contributing to overall market volume.

Market Restraints:

Intense Competition: The market is fragmented with numerous branded and generic topical corticosteroids, leading to price pressures and market share erosion.
Side Effects and Safety Concerns: Long-term or improper use of potent corticosteroids can lead to adverse effects such as skin thinning, striae, and increased susceptibility to infection, leading some prescribers to opt for alternatives.
Development of Novel Therapies: Emerging biologics and targeted therapies for severe dermatological conditions could potentially divert market share from traditional topical treatments for specific patient segments.

Who are Betaderm's Key Competitors and What is the Competitive Landscape?

Betaderm competes in a highly competitive market segment dominated by both branded and generic topical corticosteroids. Its primary competitors can be categorized by their active pharmaceutical ingredient and potency.

Direct Competitors (Potent Topical Corticosteroids):

Clobetasol Propionate (e.g., Temovate, Dermovate): A super-potent corticosteroid (Group I) that is often prescribed for more severe or resistant inflammatory dermatoses. While more potent, it carries a higher risk of side effects with long-term use.
Mometasone Furoate (e.g., Elocon): A potent corticosteroid (Group II or III depending on formulation) with a favorable safety profile, making it a common choice for moderate to severe conditions.
Fluticasone Propionate (e.g., Cutivate): A potent corticosteroid (Group II or III) widely used for various inflammatory skin conditions, known for its efficacy and tolerability.

Indirect Competitors (Mid-Potency and Lower-Potency Corticosteroids):

Triamcinolone Acetonide (e.g., Kenalog, Aristocort): A medium-potency corticosteroid (Group III or IV) often used for a broader range of inflammatory conditions, particularly where less potency is desired.
Hydrocortisone (various strengths): A low-potency corticosteroid (Group VI or VII) widely available over-the-counter and by prescription, used for mild to moderate inflammatory conditions.

Generic Competition: A significant portion of Betaderm's market share is challenged by numerous generic manufacturers offering betamethasone valerate at lower price points. This forces branded Betaderm to compete on factors such as formulation innovation, brand trust, and established physician relationships.

The competitive landscape is characterized by:

Price Sensitivity: Prescriptions are often influenced by formulary restrictions and patient co-pays, making cost a critical factor.
Physician Preference: Dermatologists develop preferences for specific formulations and active ingredients based on patient outcomes and their own clinical experience.
Therapeutic Equivalence: Regulatory bodies approve generics based on bioequivalence, allowing them to directly substitute for branded products.

What is Betaderm's Patent Status and Exclusivity Period?

Betaderm's active pharmaceutical ingredient, betamethasone valerate, is a well-established compound. The original composition of matter patents for betamethasone valerate expired decades ago. However, pharmaceutical companies may hold patents on specific formulations, delivery systems, or new uses of betamethasone valerate.

Original Composition of Matter Patent: Expired.
Formulation Patents: Manufacturers of Betaderm may hold patents on specific formulations (e.g., cream, ointment, lotion, foam) that offer improved delivery, stability, or reduced irritation. The expiration dates of these formulation patents are crucial for determining the onset of generic competition for those specific formulations. Information regarding specific formulation patent expirations is proprietary and would require in-depth patent database analysis.
Exclusivity Periods: As Betaderm is based on an old active ingredient, it does not benefit from new drug exclusivity periods granted by regulatory bodies like the FDA for novel drugs. Generic versions of betamethasone valerate have been available for many years.

The lack of patent protection on the active ingredient means that Betaderm faces ongoing generic competition, which is a primary factor in its pricing and market share dynamics. Any remaining patent exclusivity would be tied to specific innovative aspects of its current market offering, such as novel delivery mechanisms or specific combination products.

What are Betaderm's Key Commercialization Strategies and Target Audiences?

Betaderm's commercialization strategies are typical for an established topical corticosteroid, focusing on physician detailing, formulary access, and patient education.

Target Audiences:

Dermatologists: The primary prescribers. Detailing efforts focus on demonstrating efficacy for specific dermatological conditions, tolerability, and cost-effectiveness compared to alternatives.
General Practitioners (GPs) and Family Physicians: These physicians often manage common inflammatory skin conditions and represent a broad prescribing base. Education on appropriate use and indication is key.
Pharmacists: Critical for dispensing and providing patient counseling. Inclusion in pharmacy preferred drug lists and formulary acceptance are vital.
Patients: While not directly marketed to, patient education materials and physician-led discussions about managing skin conditions with Betaderm are important for adherence and continued use.

Commercialization Strategies:

Physician Detailing and Medical Education: Pharmaceutical sales representatives engage healthcare professionals to promote Betaderm, highlight its clinical profile, and provide data on its efficacy and safety. Medical conferences and continuing medical education (CME) programs are also utilized.
Formulary Access and Reimbursement: Securing inclusion on hospital and insurance formularies is paramount. This involves demonstrating clinical value and cost-effectiveness to payer organizations. Rebates and contract negotiations are common.
Product Differentiation (Formulation): Manufacturers may differentiate Betaderm through various formulations (e.g., creams for weeping lesions, ointments for dry, thick skin) that offer enhanced patient compliance or therapeutic outcomes.
Generic Competition Management: For the branded product, strategies may include loyalty programs, patient assistance programs, and emphasizing brand reliability and quality control compared to some generic options.
Post-Marketing Surveillance and Real-World Evidence: Collection and dissemination of real-world data on Betaderm's performance in diverse patient populations can strengthen its market position.

What is Betaderm's Estimated Revenue and Profitability?

Specific revenue and profitability figures for Betaderm are not publicly disclosed by its manufacturers, as it is typically part of a broader portfolio of dermatological products. However, its market position can be inferred.

Betaderm, as a branded betamethasone valerate product, operates in a segment of the topical corticosteroid market that experiences significant price erosion due to generic competition. The average selling price (ASP) for branded topical corticosteroids is considerably higher than for generics.

Revenue Estimation Factors:

Market Share: Betaderm likely holds a moderate market share within the betamethasone valerate segment, competing directly with other branded and numerous generic betamethasone valerate products.
Pricing: Branded Betaderm will be priced above generic betamethasone valerate, but likely below newer or more specialized topical therapies.
Sales Volume: Influenced by prescription volume from dermatologists and GPs, and formulary acceptance.

Profitability Factors:

Cost of Goods Sold (COGS): Manufacturing costs for topical formulations are generally moderate.
Marketing and Sales Expenses: Significant investment in physician detailing, medical education, and market access activities.
R&D Investment: For an established product like Betaderm, R&D investment is likely focused on formulation improvements rather than novel drug discovery.

Given these factors, Betaderm's profitability is likely stable but may be under pressure due to generic competition. Manufacturers often leverage established brands like Betaderm to maintain a profitable niche, especially when supported by strong physician loyalty and effective market access strategies. The profitability is dependent on the manufacturer's ability to maintain a premium price over generics and manage sales and marketing expenses efficiently.

What are the Key Regulatory Considerations for Betaderm?

Betaderm is subject to the regulatory oversight of health authorities in the markets where it is sold. Key regulatory considerations include:

Marketing Authorization: Obtaining and maintaining approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and equivalent agencies worldwide. This requires demonstrating safety, efficacy, and quality of the drug product.
Labeling and Prescribing Information: Ensuring that the product labeling accurately reflects its approved indications, contraindications, warnings, precautions, adverse reactions, and dosage and administration. This information is subject to periodic review and updates.
Good Manufacturing Practices (GMP): Adherence to strict GMP regulations is mandatory for the manufacturing of all pharmaceutical products, including Betaderm, to ensure consistent quality, safety, and purity.
Pharmacovigilance: Ongoing monitoring of the drug's safety profile in the post-market setting through adverse event reporting and risk management plans.
Post-Marketing Commitments: Regulatory authorities may require manufacturers to conduct post-marketing studies to further evaluate specific aspects of the drug's safety or efficacy in real-world populations.
Generic Drug Approval: For generic versions of Betaderm, regulatory agencies require proof of bioequivalence to the reference listed drug, along with satisfactory manufacturing standards. This regulatory pathway is a primary driver of competition for branded Betaderm.

What is the Outlook for Betaderm in the Next 5 Years?

The outlook for Betaderm over the next five years remains one of stable, albeit modest, market presence. Its trajectory will be primarily shaped by ongoing generic competition and the evolving landscape of dermatological treatments.

Key Factors Influencing the Outlook:

Sustained Demand for Topical Corticosteroids: The prevalence of inflammatory dermatological conditions is unlikely to decline significantly, ensuring continued demand for effective topical treatments like Betaderm.
Generic Dominance: Generic betamethasone valerate will continue to represent the most significant competitive threat, capping price increases and limiting market share expansion for branded Betaderm.
Physician Loyalty and Formulary Status: Manufacturers will rely on established relationships with dermatologists and broad formulary inclusion to maintain prescription volume.
Limited Innovation Potential: As a mature product, significant innovation in Betaderm's core therapeutic profile is unlikely. Efforts will focus on optimizing existing formulations or exploring niche applications.
Emergence of Biologics and Targeted Therapies: For severe cases of conditions like psoriasis and atopic dermatitis, the increasing adoption of biologics and other novel targeted therapies may reduce the reliance on potent topical corticosteroids for a segment of patients. However, topical corticosteroids will remain first-line or adjunctive therapy for milder to moderate conditions.
Healthcare Cost Containment: Continued pressure on healthcare systems to manage costs may favor the prescription of generic alternatives over branded products, unless a clear clinical advantage can be demonstrated for the branded version.

Betaderm is expected to maintain its role as a reliable, cost-effective option for managing common inflammatory skin conditions. Its market position will be characterized by volume-driven sales rather than significant price appreciation. The success of the branded product will hinge on its ability to carve out a distinct value proposition through formulation advantages, physician education, and consistent quality.

Key Takeaways

Betaderm is a potent topical corticosteroid indicated for inflammatory dermatological conditions, facing substantial competition from generic alternatives and other branded corticosteroids.
The global topical corticosteroids market is projected to grow at a CAGR of 4.3% through 2030, driven by rising skin disorder prevalence and increased healthcare expenditure.
Key competitors include Clobetasol Propionate, Mometasone Furoate, and Fluticasone Propionate, alongside a wide array of generic betamethasone valerate products.
Original composition of matter patents for betamethasone valerate have expired, making Betaderm vulnerable to generic competition.
Commercialization strategies focus on dermatologists and GPs through detailing, medical education, and securing formulary access, while managing price pressures from generics.
Specific revenue and profitability figures are not public, but profitability is likely stable but constrained by generic pricing.
Regulatory oversight includes marketing authorization, labeling, GMP compliance, and pharmacovigilance.
The outlook for Betaderm is stable, characterized by continued generic competition and reliance on established physician prescribing habits and formulary status.

FAQs

Can Betaderm be used to treat fungal infections of the skin? Betaderm is not indicated for fungal infections. Topical corticosteroids can exacerbate fungal infections by suppressing the immune response. Products containing both a corticosteroid and an antifungal agent are available for mixed infections [4].
What is the typical duration of treatment for Betaderm? Treatment duration varies based on the severity and extent of the condition. Generally, potent topical corticosteroids like Betaderm are used for short periods to control acute flares. Long-term use, especially on sensitive areas, should be avoided due to potential side effects [1].
Are there any over-the-counter (OTC) alternatives to Betaderm? While Betaderm is a prescription-strength corticosteroid, lower-potency corticosteroids such as hydrocortisone 1% are available over-the-counter for the management of mild to moderate inflammatory skin conditions.
What are the most common side effects associated with Betaderm? Common side effects include local skin reactions such as burning, itching, irritation, redness, and dryness. More serious side effects with prolonged or excessive use can include skin thinning (atrophy), stretch marks (striae), increased risk of infection, and potential systemic absorption [2].
How does Betaderm's potency compare to other common topical corticosteroids like hydrocortisone? Betaderm, containing betamethasone valerate, is classified as a potent corticosteroid (typically Group II). Hydrocortisone, in contrast, is a low-potency corticosteroid (typically Group VI or VII). This means Betaderm is significantly stronger and more effective for treating moderate to severe inflammatory skin conditions, but also carries a higher risk of side effects if misused [1].

Citations

[1] Drugs.com. (n.d.). Betamethasone topical. Retrieved from https://www.drugs.com/monograph/betamethasone-topical.html [2] National Center for Biotechnology Information. (2024). Betamethasone Valerate. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK548452/ [3] Grand View Research. (2023). Topical Corticosteroids Market Size, Share & Trends Analysis Report By Type (Clobetasol Propionate, Betamethasone, Mometasone Furoate, Hydrocortisone, Others), By Formulation, By End-use, By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/topical-corticosteroids-market [4] Mayo Clinic. (n.d.). Psoriasis. Retrieved from https://www.mayoclinic.org/diseases-conditions/psoriasis/diagnosis-treatment/drc-20355821

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	60
Patent Applications:	4,746
DailyMed Link:	BETADERM at DailyMed

BETADERM Drug Patent Profile

Which patents cover Betaderm, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Betaderm

AI Deep Research

Questions you can ask:

Summary for BETADERM

US Patents and Regulatory Information for BETADERM

BETADERM: Market Dynamics and Financial Trajectory Analysis